Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Accolla, Roberto S ^a   Tosi, Giovanna ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

CIITA; MHC class II; T helper cells; Tumor immunity; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; L19M TUMOR NECROSIS FACTOR ALPHA CONJUGATE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELPHALAN; RECOMBINANT INTERLEUKIN 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CANCER CONTROL; CANCER IMMUNIZATION; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHENOTYPE; PROTECTION; REVIEW; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS;

EID: 84864367431     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-154     Document Type: Review

References (55)

1. Vesely M, Kershaw M, Schreiber R, Smyth M. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271. 10.1146/annurev-immunol-031210-101324, 21219185.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915. 10.1038/nm1100, 1435696, 15340416.
3. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med 2011, 236:567-579.
4. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37. 10.1038/nrc1782, 16397525.
5. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A. Macrophage polarization in tumour progression. Sem Cancer Biol 2008, 18:349-355.
6. Sakaguchi S, Sakaguchi N, Asano M, Itoh MMT. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
7. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
8. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237. 10.1016/j.coi.2010.01.009, 20144856.
9. Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 2010, 21:3-10. 10.1016/j.cytogfr.2009.11.002, 2834837, 20005150.
10. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukemia cells following DNA-mediated cell transformation. Nature 1984, 311:750-752. 10.1038/311750a0, 6333639.
11. De Plaen E, Lurquin C, Lethe B, van der Bruggen P, Brichard V, Renauld JC, Coulie P, Van Pel A, Boon T. Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods 1997, 12:125-142. 10.1006/meth.1997.0462, 9184377.
12. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell therapy: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308. 10.1038/nrc2355, 2553205, 18354418.
13. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999, 154:745-754. 10.1016/S0002-9440(10)65321-7, 1866429, 10079252.
14. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003, 195:346-355. 10.1002/jcp.10290, 12704644.
15. Garrido F, Algarra I, García-Lora AM. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible " hard" lesions. Cancer Immunol Immunother 2010, 59:1601-1606. 10.1007/s00262-010-0893-2, 20625726.
16. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998, 187:693-702. 10.1084/jem.187.5.693, 2212165, 9480979.
17. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in anti-tumor immunity. Curr Opin Immunol 1998, 10:588-594. 10.1016/S0952-7915(98)80228-8, 9794842.
18. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll DM, Levitsky H. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998, 188:2357-2368. 10.1084/jem.188.12.2357, 2212434, 9858522.
19. Germain RN, Margulies DH. The biochemistry and cellular biology of antigen processing and presentation. Annu Rev Immunol 1993, 11:403-450. 10.1146/annurev.iy.11.040193.002155, 8476568.
20. Mitchison NA. Induction of immunological paralysis in two zones of dosage. Proc R Soc Lond 1964, 161(983):275-292. 10.1098/rspb.1964.0093, 14224412.
21. Makela O, Mitchison NA. The effect of antigen dosage on the response of adoptively transferred cells. Immunology 1965, 8:549-556. 1423542, 5842811.
22. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig TM, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997, 156:199-209. 10.1111/j.1600-065X.1997.tb00969.x, 9176709.
23. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004, 4:11-22. 10.1038/nrc1252, 14708024.
24. Accolla RS, Jotterand-Bellomo M, Scarpellino L, Maffei A, Carra G, Guardiola J. Air-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J Exp Med 1986, 164:369-374. 10.1084/jem.164.1.369, 2188193, 3088202.
25. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or Bare Lymphocyte Syndrome). Cell 1993, 75:135-146.
26. Meazza R, Comes A, Orengo AM, Ferrini S, Accolla RS. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol 2003, 33:1183-1192. 10.1002/eji.200323712, 12731043.
27. Harton JA, Ting JPY. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol 2000, 20:6185-6194. 10.1128/MCB.20.17.6185-6194.2000, 86093, 10938095.
28. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CAJ. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991, 353:622-627. 10.1038/353622a0, 1656276.
29. Schimd D, Pypaert M, Munz C. Antigen-loading compartments for major histocompatibility class II molecules continuously receive input from autophagosomes. Immunity 2007, 26:79-92. 10.1016/j.immuni.2006.10.018, 1805710, 17182262.
30. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993, 178:27-47. 10.1084/jem.178.1.27, 2191090, 8315383.
31. Jaraquemada D, Marti M, Long EO. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytosolic antigens to MHC class II-restricted T cells. J Exp Med 1990, 172:947-954. 10.1084/jem.172.3.947, 2188531, 2388037.
32. Mortara L, Castellani P, Meazza R, Tosi G, De Lerma Barbaro A, Procopio FA, Comes A, Zardi L, Ferrini S, Accolla RS. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res 2006, 12:3435-3443. 10.1158/1078-0432.CCR-06-0165, 16740768.
33. Frangione V, Mortara L, Castellani P, De Lerma Barbaro A, Accolla RS. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy. Int J Cancer 2010, 127:1614-1624. 10.1002/ijc.25183, 20091859.
34. Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. Int Immunol 2009, 21:655-665. 10.1093/intimm/dxp034, 19395374.
35. Sartoris S, Valle MT, De Lerma Barbaro A, Tosi G, Cestari T, D'Agostino AMMA, Manca F, Accolla RS. HLA class II expression in uninducible hepatocarcinoma cells after trasfection of the AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity. J Immunol 1998, 161:814-820.
36. Armstrong T, Clements V, Ostrand-Rosenberg S. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J Immunol 1998, 160:661-666.
37. Qi L, Rojas J, Ostrand-Rosenberg S. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol 2000, 165:5451-5461.
38. Dissanayake S, Tuera N, Ostrand-Rosenberg S. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome. J Immunol 2005, 174:1811-1819.
39. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, Thielemans K. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an Invariant chain with genetic exchange of class II-associated Invariant Chain Peptide. Cancer Res 2003, 63:5587-5594.
40. Brulet J-M, Maudoux F, Thomas S, Thielemans K, Burny A, Leo O, Bex F, Hallez S. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T celldependent protection. Eur J Immunol 2007, 37:376-384. 10.1002/eji.200636233, 17274002.
41. Mittendorf EA, Holmes JP, Murray JL, von Hofe E, Peoples GE. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther 2009, 9:71-78. 10.1517/14712590802614538, 19063694.
42. Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, et al. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol 2011, 86:918-922. 10.1002/ajh.22141, 21898529.
43. Claus R, Almstedt M, Lubbert M. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin Oncol 2005, 32:511-520. 10.1053/j.seminoncol.2005.07.024, 16210092.
44. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003, 102:4384-4392. 10.1182/blood-2003-04-1039, 12933583.
45. Balza E, Mortara L, Sassi F, Monteghirfo S, Carnemolla B, Castellani P, Neri D, Accolla RS, Zardi L, Borsi L. Targeted delivery of tumor necrosis factor-a to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res 2006, 12:2575-2582. 10.1158/1078-0432.CCR-05-2448, 16638868.
46. Mortara L, Balza E, Sassi F, Castellani P, Carnemolla B, De Lerma Barbaro A, Fossati S, Tosi G, Accolla RS, Borsi L. Therapy-induced antitumor vaccination by targeting tumor necrosis factor-a to tumor vessels in combination with melphalan. Eur J Immunol 2007, 37:3381-3392. 10.1002/eji.200737450, 18022863.
47. Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla RS, Borsi L. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Int J Cancer 2010, 127:101-110. 10.1002/ijc.25018, 19877124.
48. Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, Nishimura T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 2010, 70:2697-2706. 10.1158/0008-5472.CAN-09-2982, 20215523.
49. Lee J, Moran JP, Fenton BM, Koch CJ, Frelinger JG, Keng PC, Lord EM. Alteration of tumour response to radiation by interleukin-2 gene transfer. Br J Cancer 2000, 82:937-944. 10.1054/bjoc.1999.1022, 2374408, 10732769.
50. Yamini B, Yu X, Pytel P, Galanopoulos N, Rawlani V, Veerapong J, Bickenbach K, Weichselbaum RR. Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Clin Cancer Res 2007, 13:6217-6223. 10.1158/1078-0432.CCR-07-1421, 17947489.
51. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174:7516-7523.
52. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006, 203:1259-1271. 10.1084/jem.20052494, 3212727, 16636135.
53. Liao YP, Wang CC, Butterfield LH, Economou JS, Ribas A, Meng WS, Iwamoto KS, McBride WH. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol 2004, 173:2462-2469.
54. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011, 8:151-160. 10.1038/nrclinonc.2010.223, 21364688.
55. Lake RA, Robinson BWS. Immunotherapy and chemotherapy- a practical partnership. Nat Rev Cancer 2005, 5:397-404. 10.1038/nrc1613, 15864281.